ARCHIVES

Phase III Trial: Panobinostat Increases PFS by Four Months

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Top Officials Resign From San Antonio’s Institute for Drug Development.

January 26, 2007

LAK –IL-2 Studies Continue, Moertel Editorial Blasted

March 13, 1987

DCT To Examine Groups’ Studies, Directions, Role in 2000 A.D. Goal

June 8, 1984

New NCI Director Plans Greater Support For Translational Research, Collaboration.

March 1, 2002

Mammography Quality Standards Set, FDA User Fees Enacted; Oral Cancer Drugs Covered

October 16, 1992

Major Emphasis Switch; Outreach Core Support Ends In Favor Of Cancer Control Research

January 22, 1982